158 related articles for article (PubMed ID: 17348658)
1. Circumventing anti-androgen resistance by molecular design.
McGinley PL; Koh JT
J Am Chem Soc; 2007 Apr; 129(13):3822-3. PubMed ID: 17348658
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and preliminary investigations into novel 1,2,3-triazole-derived androgen receptor antagonists inspired by bicalutamide.
Altimari JM; Niranjan B; Risbridger GP; Schweiker SS; Lohning AE; Henderson LC
Bioorg Med Chem Lett; 2014 Nov; 24(21):4948-53. PubMed ID: 25301770
[TBL] [Abstract][Full Text] [Related]
3. Developments in nonsteroidal antiandrogens targeting the androgen receptor.
Liu B; Su L; Geng J; Liu J; Zhao G
ChemMedChem; 2010 Oct; 5(10):1651-61. PubMed ID: 20853390
[No Abstract] [Full Text] [Related]
4. Chemical Degradation of Androgen Receptor (AR) Using Bicalutamide Analog-Thalidomide PROTACs.
Kim GY; Song CW; Yang YS; Lee NR; Yoo HS; Son SH; Lee SJ; Park JS; Lee JK; Inn KS; Kim NJ
Molecules; 2021 Apr; 26(9):. PubMed ID: 33926033
[TBL] [Abstract][Full Text] [Related]
5. Discovery and biological characterization of a novel series of androgen receptor modulators.
Zhou C; Wu G; Feng Y; Li Q; Su H; Mais DE; Zhu Y; Li N; Deng Y; Yang D; Wang MW
Br J Pharmacol; 2008 May; 154(2):440-50. PubMed ID: 18414397
[TBL] [Abstract][Full Text] [Related]
6. Development of 5N-Bicalutamide, a High-Affinity Reversible Covalent Antiandrogen.
de Jesus Cortez F; Nguyen P; Truillet C; Tian B; Kuchenbecker KM; Evans MJ; Webb P; Jacobson MP; Fletterick RJ; England PM
ACS Chem Biol; 2017 Dec; 12(12):2934-2939. PubMed ID: 28981251
[TBL] [Abstract][Full Text] [Related]
7. Antiandrogens act as selective androgen receptor modulators at the proteome level in prostate cancer cells.
Brooke GN; Gamble SC; Hough MA; Begum S; Dart DA; Odontiadis M; Powell SM; Fioretti FM; Bryan RA; Waxman J; Wait R; Bevan CL
Mol Cell Proteomics; 2015 May; 14(5):1201-16. PubMed ID: 25693800
[TBL] [Abstract][Full Text] [Related]
8. Computationally identified novel diphenyl- and phenylpyridine androgen receptor antagonist structures.
Söderholm AA; Viiliäinen J; Lehtovuori PT; Eskelinen H; Roell D; Baniahmad A; Nyrönen TH
J Chem Inf Model; 2008 Sep; 48(9):1882-90. PubMed ID: 18712859
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and Biological Evaluation of Bicalutamide Analogues for the Potential Treatment of Prostate Cancer.
Kandil SB; McGuigan C; Westwell AD
Molecules; 2020 Dec; 26(1):. PubMed ID: 33374450
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanism of R-bicalutamide switching from androgen receptor antagonist to agonist induced by amino acid mutations using molecular dynamics simulations and free energy calculation.
Liu H; Han R; Li J; Liu H; Zheng L
J Comput Aided Mol Des; 2016 Dec; 30(12):1189-1200. PubMed ID: 27848066
[TBL] [Abstract][Full Text] [Related]
11. Interaction mechanism exploration of R-bicalutamide/S-1 with WT/W741L AR using molecular dynamics simulations.
Liu H; An X; Li S; Wang Y; Li J; Liu H
Mol Biosyst; 2015 Dec; 11(12):3347-54. PubMed ID: 26442831
[TBL] [Abstract][Full Text] [Related]
12. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
Gravina GL; Festuccia C; Millimaggi D; Dolo V; Tombolini V; de Vito M; Vicentini C; Bologna M
Prostate; 2008 May; 68(7):793-801. PubMed ID: 18324645
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of novel bicalutamide and enzalutamide derivatives as antiproliferative agents for the treatment of prostate cancer.
Bassetto M; Ferla S; Pertusati F; Kandil S; Westwell AD; Brancale A; McGuigan C
Eur J Med Chem; 2016 Aug; 118():230-43. PubMed ID: 27131065
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer: Could an antimalarial drug delay the onset of CRPC?
Clyne M
Nat Rev Urol; 2013 Jun; 10(6):307. PubMed ID: 23588402
[No Abstract] [Full Text] [Related]
15. A 90 kDa fragment of filamin A promotes Casodex-induced growth inhibition in Casodex-resistant androgen receptor positive C4-2 prostate cancer cells.
Wang Y; Kreisberg JI; Bedolla RG; Mikhailova M; deVere White RW; Ghosh PM
Oncogene; 2007 Sep; 26(41):6061-70. PubMed ID: 17420725
[TBL] [Abstract][Full Text] [Related]
16. Co-activator and co-repressor interplay on the human androgen receptor.
Papaioannou M; Reeb C; Asim M; Dotzlaw H; Baniahmad A
Andrologia; 2005 Dec; 37(6):211-2. PubMed ID: 16336251
[No Abstract] [Full Text] [Related]
17. Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.
Salvati ME; Balog A; Shan W; Rampulla R; Giese S; Mitt T; Furch JA; Vite GD; Attar RM; Jure-Kunkel M; Geng J; Rizzo CA; Gottardis MM; Krystek SR; Gougoutas J; Galella MA; Obermeier M; Fura A; Chandrasena G
Bioorg Med Chem Lett; 2008 Mar; 18(6):1910-5. PubMed ID: 18291644
[TBL] [Abstract][Full Text] [Related]
18. Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone-resistant prostate cancer cells and confer resistance to apoptosis.
Boutin B; Tajeddine N; Vandersmissen P; Zanou N; Van Schoor M; Mondin L; Courtoy PJ; Tombal B; Gailly P
Prostate; 2013 Jul; 73(10):1090-102. PubMed ID: 23532738
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of carborane-containing androgen receptor (AR) antagonist bearing a pyridine ring.
Ohta K; Goto T; Fijii S; Suzuki T; Ohta S; Endo Y
Bioorg Med Chem; 2008 Sep; 16(17):8022-8. PubMed ID: 18707892
[TBL] [Abstract][Full Text] [Related]
20. Molecular Basis of Bicalutamide Response Alteration of Androgen Receptor Caused by Single Nucleotide Polymorphisms: An In Silico Investigation.
Hadian N; Farsani FM; Ganjalikhany MR; Sazegar H; Sadeghi M
Crit Rev Eukaryot Gene Expr; 2019; 29(2):177-187. PubMed ID: 31679273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
